OUR TEAM

Board of Directors

Mark Beaudet – Chairman of the Board

Mark Beaudet is a co-founder of Paladin Labs Inc., a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products that was acquired by Endo International plc in 2014.

Since Paladin’s founding in 1996, Mr Beaudet served as a member of the board of directors and as the company’s Vice President of Sales & Marketing until 2011 when he became interim President and CEO.  Following Endo’s acquisition of Paladin for approximately $3 billion, Mr Beaudet joined the Endo International plc. Executive Leadership Team and continued to lead the Paladin team until his departure in June 2016.

Prior to his work with Paladin, Mr Beaudet held marketing management positions at Procter & Gamble Canada and Pizza Hut Canada. 

Mr Beaudet is currently Chairman of the Board of Cipher Pharmaceuticals Inc, a Canadian publicly traded specialty pharmaceutical company. Mr Beaudet also serves on the board of Altus Formulations Inc., a privately held drug formulation and development company.

Mr Beaudet also chairs the Board of Governors of Loyola High School and is a member of the Board of Directors of the McGill University Health Centre Foundation. He is a former member of the Board and former Chair of the Regulatory Affairs Committee of Innovative Medicines Canada (formerly Rx&D - Canada’s Research-Based Pharmaceutical Companies).

Mr Beaudet holds a bachelor’s degree in Commerce specialized in Marketing and Entrepreneurship from McGill University and is recognized as a Certified Market Research Professional (CMRP) by the Canadian Marketing Research and Intelligence Association and as an accredited pharmaceutical manufacturers representative (APMR) by the Council for Continuing Pharmaceutical Education (CCPE). 

In 2003, Mr Beaudet was a co-recipient of the EY Entrepreneur Of The Year Award in the Quebec life sciences area. In 2015, Mr Beaudet was inducted into the Canadian Healthcare Marketing Hall of Fame.

Frédéric Fasano – Director

Frédéric Fasano was appointed CEO of Servier Canada in 2011. Presently based in Laval, Quebec, Mr Fasano has over 20 years of experience in leadership roles with Servier’s international subsidiaries, including seven years in Europe (France, Italy) and two years in Latin America (Brazil, Argentina). 

Under his leadership, Servier Canada has successfully increased its engagement in Canada’s Life Sciences Eco-system. In 2014 Servier opened its new complex in Laval, housing the Center of Excellence for Clinical Research and the Center of National Professional Training. Both not only supported the growth of Servier’s activities across Canada through the deployment of pre-clinical, clinical and pharmaceutical research protocols, but also allowed the development of its talents with continuous professional education.

 

Mr Fasano has an intensive commitment to the Canadian life sciences Eco-system, including serving as the Chair of the Innovative Medicines Canada Board of Directors, and a member of the Board of Directors of Montreal InVivo. One of his signature achievements in growing the life sciences sector in Canada was the creation of a biotech company, ILKOS THERAPEUTIC INC., in partnership with the Fonds de solidarité FTQ and CTI Life Sciences Fund.

Mr Fasano is also an active advisor of the French Foreign Trade and the French Chamber of Commerce in Canada. He is proficient in French, English and Italian and holds a Pharm D from Université de Paris Sud XI and an MBA from ESSEC Business School. His extensive overseas experience in Europe, Latin America and North America in general management has enabled him to establish strong long-lasting relationships with a wide variety of life sciences stakeholders:  government leaders across Canada, universities, research centers, and other biotech companies and life sciences leaders.

 

 

 

Jean-François Leprince – Director

Since 2006, Jean-François Leprince has been a Managing Partner at CTI Life Sciences Fund, a private venture capital company funding Canadian and U.S. biotechnology companies.

After obtaining a chemical engineering degree from the Institut national supérieur de chimie industrielle, in Rouen (France), he started his working career at Dow Chemical Company in the Specialty Chemicals Division before joining the Pharmaceutical Division in 1978.

In various management and operational roles, Mr Leprince has travelled extensively to Belgium, Switzerland, France and to the Middle-East, Africa and South-East Asia. With the sale of Marion Merrell Dow to Hoechst in 1995, Mr Leprince became the Managing Director of one of Hoechst Marion Roussel’s three subsidiaries in France. In 1998, Mr Leprince became President of Hoechst Marion Roussel Canada and then of Aventis Canada as a result of the merger between Hoechst Marion Roussel and Rhone Poulenc Rorer, a role he held until the end of 2004.

While President of Aventis Canada, he served on the Board of Directors of former Rx&D (Canada's Research-Based Pharmaceutical Companies), now named Innovative Medicines Canada, and was appointed Chair in 2002.

Mr Leprince served as President & CEO of GLyPharma Therapeutic Inc., a Montreal-based CTI Life Sciences Fund portfolio company until its acquisition by Swiss-based Therachon AG in September 2018. He serves as Director of ILKOS THERAPEUTIC INC., another CTI Life Sciences Fund portfolio company resulting from a partnership with Laboratoires Servier-France.

Mr Leprince also serves on the Board of AllerGen and most recently was elected as Chairman of the Board of IRICoR. Both organizations are funded by the Networks of Centres of Excellence of Canada (NCE).

 

Serge Langford - Director

With 37 years of experience, including 28 years in venture capital, Serge Langford is an expert in the life sciences industry: he is a seasoned professional in managing investment projects and handling large transactions in this field.  Mr Langford has been with the Fonds de solidarité for 19 years and is acting as a portfolio manager in life sciences. He has also worked as managing partner at Multiple Capital and before that, Senior Investment Manager at Desjardins Venture Capital, in the same sector. Serge Langford earned a Masters degree in management science from HEC Montréal, where he gives a lecture in managerial economics, offered as part of the management certificate program.

 

 

 

Stephen D. Rubino - Director

Dr Rubino brings over 30 years of pharmaceutical leadership experience to the Board of ILKOS THERAPEUTIC INC., with emphasis in the areas of commercial operations, pharmaceutical strategy, business development and licensing, as well as investor relations. 

Dr Rubino currently serves as Chief Business Officer at Celyad SA. Dr Rubino also worked at Novartis Pharmaceuticals in a wide range of roles and therapeutic areas, the last of which was as Global Head of Business Development and New Product Marketing, responsible for developing and building the product pipeline for Novartis Cell & Gene Therapies Unit.

Prior to Novartis, Dr Rubino worked for Schering–Plough (Merck) where his last role was Head of the Global Solid Tumour Oncology & Autoimmune Business Unit responsible for the licensing and launch of Remicade, as well as for the launch and commercialization of several global oncology brands. 

Dr Rubino obtained a Ph.D. from Weill Cornell University and an MBA. from Baruch University.

 

Monique Champagne – Director

Monique Champagne has over 30 years of experience in clinical research, drug development and regulatory affairs, acquired in the pharmaceutical and biotechnology industries. A creative manager, she has extensive experience and expertise in the first phases of oncology drug development, in clinical development in various therapeutic areas, clinical operations management, regulatory affairs, integration and improvement of operational processes, as well as in managing international projects and professional relations with business partners.

Prior to joining ILKOS THERAPEUTIC INC., Ms Champagne was Vice-President, Clinical Research and Regulatory Affairs, at Telesta Therapeutics. Before that, she held management positions at, among others, Xanthus Life Sciences, Supratek Pharma, PricewaterhouseCoopers, Quintiles (IQVIA) and Wyeth-Ayerst (Pfizer).

Monique Champagne holds a bachelor’s degree in pharmacy (B.Pharm.), a master’s degree in pharmaceutical sciences (M.Sc.) and a pharmacist licence in Quebec.